DB00051 in ulcerative colitis : hypes and hopes . IMPORTANCE OF THE FIELD : The advent of anti- P01375 -α monoclonal antibodies has dramatically changed the management of inflammatory bowel diseases ( Q9UKU7 ) . Unlike Crohn 's disease ( CD ) , only one anti- P01375 -α agent , infliximab , is currently approved for active moderate-to-severe ulcerative colitis ( UC ) . DB00051 is a fully human anti- P01375 -α antibody that is effective and safe for the treatment of luminal and fistulising CD . AREAS COVERED IN THIS REVIEW : This review of the literature summarizes available data on of efficacy and safety profile adalimumab in patients with UC . WHAT THE READER WILL GAIN : DB00051 may be effective in inducing and maintaining clinical remission in patients with moderate-to-severe UC . It may also induce mucosal healing and reduce the need for colectomy in patients with severe disease . The safety profile of the drug in UC is consistent with previous experience with this drug in CD . TAKE HOME MESSAGE : DB00051 may be effective and well tolerated in UC . Its efficacy in maintaining clinical remission needs to be confirmed in a randomized controlled trial .